Biotech | March 14, 2022
Clarivate deals report highlights emerging trends in biopharma deal-making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
Price was the key driver for the period
Sense anticipates launching Veros Covid-19 in Europe this quarter, initially in Ireland, Benelux and the Nordic regions
JEEN’s portfolio includes a diverse range of specialized active ingredients, botanical extracts, and complexes serving functional applications for skin and hair care
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
Subscribe To Our Newsletter & Stay Updated
